7h agoSeeking AlphaBEARISH 18Product/PR
ArriVent plunges as lead asset fails in late-stage cancer trial
ArriVent BioPharma (AVBP) stock plunges 50% as lead asset fails in a late-stage trial for a type of lung cancer. Read more here.
Archived explainer. For the current picture see today's AVBP page.
Why Is ARRIVENT BIOPHARMA I (AVBP) Stock Down Today?
By the Top Tier Newswire AI Desk · October 6, 2026 at 12:22 PM ET · reviewed against 10 wire stories
ARRIVENT BIOPHARMA I (AVBP) is down -46.91% in the latest session. Our newswire has captured 10 stories on AVBP across 8 sources in the last 36 hours, with AI sentiment reading bearish (avg 31/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why AVBP stock is down today
ArriVent Biopharma (AVBP) stock fell by 46.91% to $15.11 in a single session after the company announced that its lead asset, firmonertinib, failed to meet the primary endpoint in a late-stage Phase 3 clinical trial for a type of lung cancer. The announcement triggered a sharp selloff, with the stock opening at $28.35 and falling to an intra-day low of $10.25 before stabilizing slightly in the final minutes of trading.
What Happened
ArriVent disclosed that its global Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC) did not meet the primary endpoint of progression-free survival (PFS) by blinded independent central review. This outcome significantly reduced the perceived value of the drug candidate, which had been viewed as a key development asset for the company. The stock initially opened near $28 but quickly declined as the news became widely known. By 8:30 AM ET, the stock had fallen to $10.25, a level not seen since the early days of the 52-week trading range. The session saw 10.1 million shares traded, a volume 17.6 times the 3-month average.
What The Data Shows
The stock has been in a downward trend over the last 8 sessions, declining 5.4% from $30.10 to $28.46. The 30-day average sentiment score was 36 out of 100, dropping to 31 in the last 7 days, indicating a deteriorating outlook. On October 6, the stock printed 4 fresh 52-week lows, while also hitting 20 new 52-week highs, suggesting a highly volatile and mixed market reaction. The stock currently trades at a market cap of $1.4 billion, with a trailing 12-month EPS of -3.70, highlighting its unprofitable status.
What To Watch
The stock has no scheduled earnings date in the near term. Investors should monitor the breadth of coverage and sentiment shifts in the coming days, as well as any follow-up statements or strategic actions from the company in response to the trial results.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AVBP by the numbers
Last: $15.11Session: -46.91%7 sessions: -46.96%Coverage: 10 stories / 8 sourcesAI sentiment: 31/100 (bearish)Mkt cap: $1.4B52w: $17.00 to $35.83
The headlines behind the move
8h agoThe FlyBEARISH 18Earnings
ArriVent sinks 60% to $11.50 after Phase 3 study miss
8h agoThe FlyBEARISH 28Product/PR
ArriVent says Phase 3 firmonertinib trial did not meet endpoint
8h agoReutersBEARISH 18Product/PR
ArriVent's oral lung cancer therapy fails late-stage trial, shares plunge
8h agoMarketChameleonBEARISH 28Earnings
AVBP Shares React After FURVENT Misses Primary PFS Endpoint Despite Higher Confirmed Response Rate at 240 mg October 6, 2026
ArriVent BioPharma (AVBP) said its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion-mutant NSCLC did not meet the primary endpoint of PFS by blinded independent central review. The company highlighted secondary endpoint signals, including higher confirmed response rates at 240 mg and more favorable investigator-assessed PFS, while reporting no new safety signals and broadly similar high-grade TEAE rates across arms.
8h agoInvesting.com MarketsBEARISH 34General
Why is Arrivent Biopharma stock collapsing today?
Why is Arrivent Biopharma stock collapsing today?
8h agoInvesting.com MarketsBEARISH 22Earnings
ArriVent stock tumbles 60% after trial misses primary endpoint
ArriVent stock tumbles 60% after trial misses primary endpoint
9h agoTipRanksBEARISH 28Product/PR
ArriVent’s FURVENT Phase 3 Trial Misses Primary Endpoint
ArriVent BioPharma, Inc. ( ($AVBP) ) has provided an announcement. On October 6, 2026, ArriVent reported that its global Phase 3 FURVENT trial of firmonertinib as a...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on AVBP: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AVBP move explainers: 2026-10-06